QUALTRUXA

Serial Number 97711217
606

Registration Progress

Application Filed
Dec 9, 2022
Under Examination
Dec 5, 2023
Approved for Publication
Oct 10, 2023
Published for Opposition
Oct 10, 2023
Registered

Attorney Assistance

Abandonment Notice E-Mailed - No Use Statement Filed
Due: Dec 01, 2025 23 days
Revival assistance for abandoned trademark

Trademark Image

QUALTRUXA

Basic Information

Serial Number
97711217
Filing Date
December 9, 2022
Published for Opposition
October 10, 2023
Abandonment Date
October 1, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Oct 1, 2025
Classes
005

Rights Holder

Aldeyra Therapeutics, Inc.

03
Address
131 Hartwell Avenue, Suite 320
Lexington, MA 02421

Ownership History

Aldeyra Therapeutics, Inc.

Original Applicant
03
Lexington, MA

Aldeyra Therapeutics, Inc.

Owner at Publication
03
Lexington, MA

Legal Representation

Attorney
Nathan T. Harris

USPTO Deadlines

Next Deadline
23 days remaining
Abandonment Notice E-Mailed - No Use Statement Filed
Due Date
December 01, 2025

Application History

14 events
Date Code Type Description Documents
Oct 1, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Oct 1, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Jun 13, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 4, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jun 4, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Jun 4, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 5, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Oct 10, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 10, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Sep 20, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Sep 6, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 6, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 7, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 13, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceuticals in the nature of an injectable solution for intravitreal use  for the prevention of eye conditions including proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and retinitis pigmentosa

Classification

International Classes
005